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PURPOSE: Although drug-drug interactions constitute only a small proportion of adverse drug reactions, they are often predictable
and therefore avoidable or manageable. There are few studies on drug-drug interactions from Brazil. This study aimed to assess
the frequency of drug-drug interactions in prescriptions and their potential clinical significance in patients of a Brazilian teaching
hospital.
METHODS: From January to April 2004, a sample of 1785 drug prescriptions was drawn from a total of 11,250. Drug-drug
interactions were identified by using Micromedex® DrugReax® System. Patients´ records with major drug-drug interactions were
reviewed by a pharmacist and a medical doctor looking for signs, symptoms, and lab tests that could indicate adverse drug
reactions due to such interactions.
RESULTS: From the 1785 prescriptions examined, 1089 (61%) were from the male adult ward. Patients’ average age was 52.7
years (SD = 18.9; range, 12-98). The median number of drugs in each prescription was 7 (range, 2-26). At least 1 drug-drug
interactions was present in 887 (49.7%) prescriptions. Regarding the severity of the clinical result, the interactions were classified
as minor (20; 2.3%), moderate (184; 20.7%), major (30; 3.4%), and undetermined because of an incidence of more than 1 interaction
in a single patient (653; 73.6%). From the 30 patients with major interactions, 17 (56.7%) presented adverse drug reactions
induced by exposure to a major drug-drug interaction.
CONCLUSIONS: Patients did suffer adverse drug reactions from major drug-drug interactions. Many physicians may be unaware
of drug-drug interactions. Education, computerized prescribing systems and drug information, collaborative drug selection, and
pharmaceutical care are strongly encouraged for physicians and pharmacists.
KEYWORDS: Prescriptions. Drug-drug interactions. Teaching Hospital. Pharmacovigilance. Drug utilization.
INTRODUCTION
Drug-drug interactions (DDI) are a cause of adverse drug
reactions, resulting in adverse outcomes associated with drug
therapy.1,2 The literature on drug interactions is generally re-
lated to DDI mechanisms, drug pharmacokinetic studies, and
clinical cases.3,4 The pharmacoepidemiology of drug inter-
actions has been less explored.
Hospital stay may be associated with relevant changes
in patient care. In general, close monitoring of medical care
is guaranteed during the hospital stay. Patients without
therapeutic care are more exposed to drug-related problems
that may include potential DDI.5,6
At least 15% of the patients admitted to hospitals have
1 DDI at admission.1,7-9 The risk of DDI can increase in
the hospital because new drugs are often added to an ex-
isting drug therapy.10 Drug-drug interactions are often pre-
dictable and, therefore, avoidable or manageable, but the
reactions caused by them are mostly unknown. The present
study aimed to assess the prevalence of DDI in the hospi-
tal prescriptions for adult inpatients and describe their char-
acteristics and the adverse reactions caused by ‘major’ DDI.
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METHODS
A drug utilization study was carried out using data from
the prescriptions of a Brazilian teaching hospital. The hos-
pital is a 300-bed teaching public institution that is also a
referral center for hospital care. During the period of this
study, hospitalization length for inpatients varied from 1
to 8 days. The hospital, as for many in Brazil, does not
have electronic prescription capability. Once a day, medi-
cal doctors prescribe drugs necessary for 24 hours of hos-
pitalization. More than 1 drug can be prescribed at the same
time.
During a 4-month period, approximately 11,250 pre-
scriptions were dispensed. Only patients who were 12 years
old or more were in these wards, separated by gender. Pre-
scriptions containing 2 or more drugs were selected once
a week from January to April 2004. Prescriptions for pa-
tients of both genders were included in this study. All drug
groups were included and classified according to the Ana-
tomical-Therapeutic-Chemical Classification (ATC code,
level 2 – WHO, 2004).11 The total number of prescriptions
selected for this study was 1785, which corresponds to
15.8% from the entire population. The ratio of men to
women in the study was maintained as 60/40, to match the
hospital’s male/female ward ratio.
Drug-drug interactions were identified using the
Micromedex® DrugReax® System.12 The DrugReax System
information contains a dictionary of more than 8,000
unique drug terms, and it distinguishes trade names from
equivalent generic names, eliminating possible duplication
of interaction data on the screen. This system is drug-spe-
cific rather than class-specific. All the drugs prescribed
must be selected on the screen to have DDI calculated. Up
to 128 concurrent clinical conflicts can be reviewed. The
program also provides information about clinical conse-
quences or adverse drug reactions that could result from a
DDI; it characterizes the underlying mechanism and clas-
sifies onset of adverse drug reactions (rapid, delayed), se-
verity (minor, moderate, major), and how well the DDI is
documented in the literature (excellent, good, fair, poor,
unlikely). The Micromedex DrugReax System’s definitions
about onset, severity, and documentation were accepted for
use in the study, as follows:12
Onset
• Rapid: Onset of clinical conflict or adverse effects ex-
pected within 24 hours of drug administration.
• Delayed: Onset of clinical conflict or adverse effects not
expected to appear within the first 24 hours following
drug administration.
Severity
• Major: The interaction may be life-threatening and/or re-
quire medical intervention to minimize or prevent se-
rious adverse effects.
• Moderate: The interaction may result in an exacerbation
of the patient’s condition and/or require an alteration
in therapy.
• Minor: The interaction would have limited clinical ef-
fects. Manifestations may include an increase in the fre-
quency or severity of side effects but generally would
not require a major alteration in therapy.
Documentation
• Excellent: Controlled studies have clearly established the
existence of the interaction.
• Good: Documentation strongly suggests the interaction
exists, but well-controlled studies are lacking.
• Fair: Available documentation is poor, but pharmacologic
considerations lead clinicians to suspect the interaction
exists; or, documentation is good for a pharmaco-
logically similar drug.
• Poor: Documentation is poor, such as limited case reports;
but the clinical conflict is theoretically possible.
• Unlikely: Documentation is poor and lacks a sound
pharmacologic basis.
Each prescription with a ‘major’ DDI led to a patient
record, which was examined by a physician and a phar-
macist to find signs, symptoms, and lab test results that
could confirm adverse reactions resulting from the ‘major’
DDI.
Data were presented as proportions, means and stand-
ard deviations, or medians. Descriptive analysis was con-
ducted in Excel® version 7.0.
This study was previously evaluated and approved by
the Committee of Ethic of the University.
RESULTS
Prescriptions
In this study, 1785 prescriptions were analyzed; 1089
(61%) were from the male adult ward and 696 (39.0%)
from female ward. The average age of the patients was 52.7
± 18.9 years (range, 12-98 years). Prescriptions came from
patients who had been hospitalized in the following areas:
gastroenterology (279; 15.6%), orthopedics (269; 15.1%),
cardiovascular (240; 13.4%), emergency surgery (146;
8.2%), neurology (143; 8.0%), pneumology (103; 5.8%);
and others (605; 33.9%).
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Number of drugs prescribed
Each prescription had a median of 7 drugs (range, 2-
26 different drugs). Analgesics, drugs for gastrointestinal
disorders, and antibacterial drugs for systemic use were the
most prescribed therapeutic drug classes. Metamizole so-
dium (n = 1138; 63.8%) was the analgesic present in al-
most all prescriptions, followed at a distance by tramadol
(n = 289; 16.2%). Metoclopramide (n = 1116; 62.5%) was
the most prescribed drug for functional gastrointestinal dis-
orders. Metronidazole (n = 188, 10.5%) and ciprofloxacin
(n = 151, 8.5%) were the most prescribed antibacterial
drugs for systemic use. The median number of therapeutic
drug classes in each prescription was 4 (range, 1-8).
Prevalence of drug-drug interactions (DDI)
From the 1785 prescriptions analyzed, DDI was iden-
tified in 887 (49.7%). Prescriptions presenting DDI came
from cardiovascular (n = 192; 21.6%), gastroenterology
(101; 11.4%), emergency surgeries (94; 10.6%), orthoped-
ics (90; 10.1%), neurology (73; 8.2%), pneumology (50;
5.6%), and others (287; 32.4%). The number of DDI per
prescription varied from 1 to 22 with a median of 3.
Captopril + spironolactone (18; 2.0%) and digoxin + hy-
drochlorothiazide (16; 1.6%) were the most common ‘ma-
jor’ DDI in our sample.
Only 234 (26.4% of 887) prescriptions had a single
DDI, while 653 (73.6% of 887) prescriptions presented
more than 1. Regarding the 234 prescriptions having only
1 DDI, an underlying pharmacodynamic mechanism was
identified for 102 (43.5%), while a pharmacokinetic mecha-
nism was identified for 44 (18.8%); other types of mecha-
nisms were identified for 83 (35.5%), and mechanisms were
unknown for 5 (2.2%). The onset of expected adverse drug
reaction as a result of a DDI was classified as ‘delayed’ in
114 prescriptions (48.7%), while it was ‘rapid’ in 120
(51.3%). The documentation in the literature for DDI was
classified as ‘excellent’ or ‘good’ for 69 (29.5%) prescrip-
tions, ‘fair’ for 120 (51.3%), ‘poor’ for 41 (17.5%), and ‘un-
likely’ for 4 (1.7%) From the 234 prescriptions with a sin-
gle DDI, the following classifications of the severity of the
potential adverse drug reaction were made: ‘major’, 30 pre-
scriptions (12.8%); ‘moderate’, 184 (78.6%); and ‘minor’,
20 (8.6%).
Clinical relevance
The DDI detected in our sample were easily manage-
able, either by substituting another drug (256; 28.9%), by
adjusting the dose (166; 18.9%), by supplementing the pre-
scribed drugs with another drug (71; 8.0%), or by closely
monitoring clinical symptoms and lab tests results (52;
5.9%). However, at least 64 prescriptions (7.2%) had 1 ‘ma-
jor’ DDI that should have been avoided. No management
was suggested by Micromedex for 278 prescriptions
(31.3%).
The expected adverse drug reactions resulting from the
DDI were hypertension (45; 19.2%), hemorrhage (34;
14.5%), inflammation (12; 5.1%), hypoglycemia (8; 3.4%),
and others (135; 57.7%).
The 30 prescriptions with 1 ‘major’ DDI led to patient
records, which were examined to look for evidence that
suggested that adverse drug reactions resulted from the
DDI. The following DDI and adverse drug reactions were
identified in 17 (56.7%) of these 30 examined records: ace-
tylsalicylic acid + warfarin [gastric hemorrhage],
amiodarone + digoxin [digitalic toxicity], amitriptyline +
clonidine [hypertension], captopril + spironolactone
[hyperkalemia and changes in the ECG], potassium chlo-
ride + spironolactone [hyperkalemia], digoxin + hydrochlo-
rothiazide [digitalic toxicity], and isoniazid + rifampin
[hepatotoxicity]. See Table 1 for more information about
the patients whose prescriptions had a ‘major’ DDI and
whose records showed signs and symptoms of adverse drug
reactions.
DISCUSSION
The present study highlights the detection of DDI preva-
lence using a computer program to check prescriptions for
inpatients in a Brazilian teaching hospital. In our study, al-
most 50% of the prescriptions presented at least 1 DDI.
This prevalence was higher than others found in similar
Brazilian studies.9,13,14 Miyasaka and Atallah9 found that in
prescriptions for psychiatric patients, 22% had DDI;
Meiners and Bergsten-Mendes13 found that in pediatric pre-
scriptions, 32% had DDI. This discrepancy could have oc-
curred because of the different designs of the studies. Dias14
found that in prescriptions of a Brazilian hospital in a study
having a design similar to ours, 38% had DDI. Possible
causes of this difference in DDI prevalence may be due to
aspects related to population, year and period of study, the
sequence of actions and decisions used to provide drug
therapy, hospital pharmacists’ work, and electronic drug
information availability in the hospital.
Several DDI were detected in most of the prescriptions
of our sample. We did not find information about the clini-
cal consequences of more than 1 DDI in the literature; how-
ever, if 1 DDI can be life-threatening, we believe it is safe
to assume that 2 or more DDI may even more hazardous
for the patient.
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In our study, only 234 prescriptions (26.4% from 887)
presented a single DDI, and 30 of them (12.8% of the 234)
were expected to have ‘major’ clinical consequence. More
than half of the patients (56.7% of the 30) with a ‘major’
DDI at prescription did present the expected adverse drug
reaction during hospitalization time.
We cannot quantify how many of the identified DDI
were known by the physicians, but we assume that they
were possibly unaware of the potential risk associated with
certain combinations. To better quantify the clinical rel-
evance of potential interacting drug combinations during
hospital stay, a prospective design would be necessary, in-
cluding a follow-up long enough after discharge to assess
the outcomes of DDI even for those with a delayed onset.
Moreover, the clinical relevance of a DDI is often catego-
rized along 2 dimensions,15 ie, the expected ‘severity’ of a
patient’s physical reaction to a DDI and the ‘documenta-
tion’ (the amount and quality of research that suggest
whether a particular DDI will indeed occur in human be-
ings). In fact, the clinical effects of any DDI, regardless of
how well it is documented, do not occur in every patient
or at the same level of intensity. They depend on patient-
related factors that usually require individual assessment.16
However, our results showed that some patients had suf-
fered adverse reactions from ‘major’ DDI.
The potential adverse clinical consequences resulting
from a specific interacting drug combination may some-
times be counteracted by prescribing an additional drug.
Moreover, the sequence of drug administration and patient-
related factors may be crucial for the occurrence of adverse
effects, but generally, drug interaction programs do not con-
sider these aspects. All these factors could have resulted
in the overestimation of the risk of DDI, so evaluations for
actual adverse drug effects were done by screening the
records of patients who had a ‘major’ DDI pair prescribed.
To assess the clinical relevance of a DDI, it would be
highly recommended to determine how often it appears in
prescriptions. Our work followed a pharmacoepidemiologic
design, which is one of the contributions of this study. Lit-
erature on DDI prevalence is scarce, since drug interaction
studies give no information on the total number of patients
exposed to each drug combination.3,4 Additionally, DDI
studies of clinical relevance are often carried out by a small
group of volunteers, or arise from case series with specific
patients or drugs.
This study focused on the epidemiology of severe DDI
caused by drugs prescribed and their clinical manifestations
in patients. Limitations of this study were due to the ret-
rospective design.
Other limitations of this study were closely related to
the information provided by different sources. There is only
a partial agreement among DDI compendia.7,17 In this study,
a compendium that lists most of the known interactions was
used. This may have resulted in an overestimation of DDI
in the whole sample.
The ‘major’ drug interacting combinations have been
associated with clinically relevant adverse reactions.12
Pharmaceutical care, electronic drug information, and
pharmacotherapy evaluation of prescriptions could contrib-
ute to better patient health outcomes.18
A computerized drug-interaction program may be a
valuable and helpful tool to check for DDI, but it has to
be combined with clinical pharmacological experience and
expertise as well as the knowledge of relevant patient-re-
Table 1 - Number of patients whose prescriptions had a ‘major’ drug-drug interaction (DDI) and whose records showed
signs and symptoms of adverse drug reactions (ADR), by disease classification and age
Disease classification Age range Number of patients with ADRas a result of a ‘major’ DDI pair
at admission (years) ASA+ Wa A+Db A+Cc C+Sd P+Se D+Hf I+Rg
Cardiovascular <59 2 1 2 1 - - -
60-79 - - - - 1 - -
>80 1 - - - - - -
Gastroenterologic <59 - - - - - - 1
60-79 - - 1 1 1 - -
>80 - - - - - - -
Neurologic <59 - - - - - - -
60-79 1 - - - - - -
>80 - - - - - - -
Pulmonary <59 - - 1 - - - -
60-79 - - - 1 1 1 -
>80 - - - - - - -
Total patients with 4 1 4 3 3 1 1
ADRh
a
 acetylsalicilic acid + warfarin; b amiodarone + digoxin; c amitryptiline + clonidine; d captopril + spironolactone; e potassium chloride + spironolactone; f
digoxin + hydrochlorothiazide; g isoniazide + rifampin; h adverse drug reaction
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lated factors.19,20 This also implies that computer programs
should place more emphasis on how to detect and deal with
the clinical consequences of a DDI.
CONCLUSION
Drug-drug interaction should be suspected anytime a
new or an unexpected effect occurs and complicates the
clinical management of a patient in a setting where the pa-
tient is receiving at least 2 interacting drugs.21-24 This study
is a contribution to the epidemiologic data on prevalence
of DDI in prescriptions and clinical manifestation of the
‘major’ DDI.
Brazilian pharmacists are generally involved adminis-
tratively rather than clinically,25 and Brazilian hospitals
rarely offer pharmaceutical care or drug information serv-
ices.26 Prescriptions should be screened at least for ‘major’
DDI. Prescriptions of drugs that are commonly involved
in ‘major’ DDI, like digoxin and warfarin, should be
analyzed by a clinical pharmacist prior to drug dispensing.
Patients should also be closely monitored for adverse drug
reactions.
Education of health professionals, computerized sys-
tems for prescription and drug information, as well as col-
laborative drug selection and pharmaceutical care are some
of the possible solutions to the problem. The quality of Bra-
zilian health care practices and drug use process need fur-
ther investigation. All people deserve to be better cared for.
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RESUMO
Cruciol-Souza JM, Thomson JC. Um estudo farmacoepi-
demiológico de interações medicamentosas em um hospi-
tal universitário brasileiro. Clinics. 2006;61(6):515-20.
INTRODUÇÃO: Embora as interações medicamentosas
constituam uma pequena parcela das reações adversas a
medicamentos, elas geralmente são previsíveis e às vezes
podem ser evitadas. As prevalências de interações
medicamentosas em hospitais são escassas no Brasil.
OBJETIVO: Avaliar a prevalência de interações medica-
mentosas em prescrições hospitalares e seu significado clí-
nico em pacientes de um hospital universitário brasileiro.
MÉTODOS: Uma amostra de 1785 prescrições de enfer-
maria de adultos foi coletada de um total de 11.250 avia-
das no período de janeiro a abril de 2004. As interações
medicamentosas foram identificadas pelo Micromedex.
Prontuários de pacientes com interações medicamentosas
graves foram examinados por um médico e uma farmacêu-
tica a busca de resultados laboratoriais que confirmassem
a ocorrência da interação medicamentosa.
RESULTADOS: As prescrições eram de pacientes mascu-
linos (1089; 61%) em sua maioria. A idade média dos pa-
cientes foi de 52,7 anos (DP=18,9; variação de 12 a 98
anos). Cada paciente recebeu em média 7 medicamentos
(variando de 2 a 26). Ao menos 887 (49,7%) das prescri-
ções continham interação medicamentosa. As prescrições
continham interação medicamentosa classificadas como
leve (55; 3.1%), moderada (421; 23.6%) e grave (90; 5.0%).
Em 321 (17.9%) prescrições foram encontradas mais de
uma interação medicamentosa, cujo resultado clínico é des-
conhecido. Uma amostra de 33 prontuários com interações
medicamentosas graves foram avaliadas, destes, 17 (51.5%)
apresentaram reações adversas a medicamentos induzida
por uma interação medicamentosa grave.
CONCLUSÃO: Um grande número de pacientes sofre rea-
ções adversas a medicamentos como resultado de interações
medicamentosas graves. Acreditamos que a maioria dos mé-
dicos desconheça a ocorrência de interações medicamentosas.
Educação continuada, sistema computadorizado para prescri-
ção, seleção de medicamentos em parceria com farmacêuti-
cos e monitoramento farmacoterapêutico dos pacientes são
recomendações para os profissionais da saúde.
UNITERMOS: Prescrições. Interações medicamentosas.
Hospital Universitário. Farmacovigilância. Utilização de
Medicamentos.
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